BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32035706)

  • 1. Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa.
    Madhi SA; Moreira M; Koen A; van Niekerk N; de Gouveia L; Jose L; Cutland CL; François N; Schoonbroodt S; Ruiz-Guiñazú J; Yarzabal JP; Borys D; Schuerman L
    Vaccine; 2020 Feb; 38(10):2350-2360. PubMed ID: 32035706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status.
    Madhi SA; Koen A; Jose L; van Niekerk N; Adrian PV; Cutland C; François N; Ruiz-Guiñazú J; Yarzabal JP; Moreira M; Borys D; Schuerman L
    Medicine (Baltimore); 2017 Jan; 96(2):e5881. PubMed ID: 28079828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials.
    Nunes MC; Moreira M; Koen A; van Niekerk N; Jose L; Cutland CL; François N; Schoonbroodt S; Ruiz-Guiñazú J; Yarzabal JP; Borys D; Schuerman L; Madhi SA
    Expert Rev Vaccines; 2020 Dec; 19(12):1177-1189. PubMed ID: 33245004
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage.
    Prymula R; Hanovcova I; Splino M; Kriz P; Motlova J; Lebedova V; Lommel P; Kaliskova E; Pascal T; Borys D; Schuerman L
    Vaccine; 2011 Feb; 29(10):1959-67. PubMed ID: 21215830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial.
    Madhi SA; Koen A; Jose L; Moreira M; van Niekerk N; Cutland C; François N; Ruiz-Guiñazú J; Yarzabal JP; Borys D; Schuerman L
    Expert Rev Vaccines; 2017 Jun; 16(6):641-656. PubMed ID: 28425818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol.
    Prymula R; Habib A; François N; Borys D; Schuerman L
    Vaccine; 2013 Apr; 31(16):2080-8. PubMed ID: 23391599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
    Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial.
    Hammitt LL; Ojal J; Bashraheil M; Morpeth SC; Karani A; Habib A; Borys D; Goldblatt D; Scott JA
    PLoS One; 2014; 9(1):e85459. PubMed ID: 24465570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial.
    Beissbarth J; Wilson N; Arrowsmith B; Binks MJ; Oguoma VM; Lawrence K; Llewellyn A; Mulholland EK; Santosham M; Morris PS; Smith-Vaughan HC; Cheng AC; Leach AJ
    Vaccine; 2021 Apr; 39(16):2264-2273. PubMed ID: 33766422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal study on Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus nasopharyngeal colonization in HIV-infected and -uninfected infants vaccinated with pneumococcal conjugate vaccine.
    Madhi SA; Izu A; Nunes MC; Violari A; Cotton MF; Jean-Philippe P; Klugman KP; von Gottberg A; van Niekerk N; Adrian PV;
    Vaccine; 2015 May; 33(23):2662-9. PubMed ID: 25910923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland.
    Vesikari T; Forsten A; Seppä I; Kaijalainen T; Puumalainen T; Soininen A; Traskine M; Lommel P; Schoonbroodt S; Hezareh M; Moreira M; Borys D; Schuerman L
    J Pediatric Infect Dis Soc; 2016 Sep; 5(3):237-248. PubMed ID: 27125273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil.
    Brandileone MC; Zanella RC; Almeida SCG; Brandao AP; Ribeiro AF; Carvalhanas TMP; Sato H; Andrade AL; Verani JR;
    Vaccine; 2016 Nov; 34(46):5604-5611. PubMed ID: 27692770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study.
    Zaman K; Zaman SF; Zaman F; Aziz A; Faisal SB; Traskine M; Habib MA; Ruiz-Guiñazú J; Borys D
    Vaccine; 2018 Jan; 36(5):698-706. PubMed ID: 29277353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 10-Valent pneumococcal non-typeable
    Oguoma VM; Wilson N; Mulholland K; Santosham M; Torzillo P; McIntyre P; Smith-Vaughan H; Balloch A; Chatfield M; Lehmann D; Binks MJ; Chang A; Carapetis J; Krause V; Andrews R; Snelling T; Licciardi P; Morris P; Leach AJ
    BMJ Open; 2020 May; 10(5):e033511. PubMed ID: 32448790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.
    Sáez-Llorens X; Rowley S; Wong D; Rodríguez M; Calvo A; Troitiño M; Salas A; Vega V; Castrejón MM; Lommel P; Pascal TG; Hausdorff WP; Borys D; Ruiz-Guiñazú J; Ortega-Barría E; Yarzabal JP; Schuerman L
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-16. PubMed ID: 28368738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia.
    Lim FS; Koh MT; Tan KK; Chan PC; Chong CY; Shung Yehudi YW; Teoh YL; Shafi F; Hezareh M; Swinnen K; Borys D
    BMC Infect Dis; 2014 Oct; 14():530. PubMed ID: 25278086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children previously vaccinated with various pneumococcal conjugate vaccine regimes.
    Boelsen LK; Dunne EM; Lamb KE; Bright K; Cheung YB; Tikoduadua L; Russell FM; Mulholland EK; Licciardi PV; Satzke C
    Vaccine; 2015 Oct; 33(42):5708-5714. PubMed ID: 26232540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable
    de Los Santos AM; Rodríguez-Weber MA; Sánchez-Márquez P; Traskine M; Carreño-Manjarrez R; Cervantes-Apolinar MY; Strezova A; Ruiz-Guiñazú J; Ortega-Barria E; Borys D
    Expert Rev Vaccines; 2020 Nov; 19(11):995-1010. PubMed ID: 33297773
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
    Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Owiafe PK; Worwui A; Idoko OT; Owolabi O; Kampmann B; Greenwood BM; Alderson M; Traskine M; Swinnen K; Verlant V; Dobbelaere K; Borys D
    Vaccine; 2019 May; 37(19):2586-2599. PubMed ID: 30975570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.